Last reviewed · How we verify
oPLB
oPLB is a long-acting buprenorphine formulation designed to provide sustained opioid agonist therapy for opioid use disorder.
oPLB is a long-acting buprenorphine formulation designed to provide sustained opioid agonist therapy for opioid use disorder. Used for Opioid use disorder.
At a glance
| Generic name | oPLB |
|---|---|
| Also known as | Placebo tablets |
| Sponsor | National Institute on Drug Abuse (NIDA) |
| Drug class | Partial mu-opioid receptor agonist |
| Target | Mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | Phase 3 |
Mechanism of action
oPLB delivers buprenorphine, a partial mu-opioid receptor agonist, in an extended-release formulation to reduce withdrawal symptoms and cravings in patients with opioid dependence. The long-acting delivery system aims to improve treatment adherence and reduce the frequency of dosing compared to daily formulations.
Approved indications
- Opioid use disorder
Common side effects
- Headache
- Nausea
- Constipation
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oPLB CI brief — competitive landscape report
- oPLB updates RSS · CI watch RSS
- National Institute on Drug Abuse (NIDA) portfolio CI